6-Gingerol Activates PI3K/Akt and Inhibits Apoptosis to Attenuate Myocardial Ischemia/Reperfusion Injury

Xiangwei Lv, Tongtong Xu, Qi Wu, Yao Zhou, Guidong Huang, Yongnan Xu, and Guoqiang Zhong

1Department of Cardiology, First Affiliated Hospital of Guangxi Medical University, Nanning, Guangxi Zhuang Autonomous Region 530021, China
2Department of Integrated Traditional Chinese and Western Medicine, First Affiliated Hospital of Guilin Medical University, Guilin, Guangxi Zhuang Autonomous Region 541001, China
3Department of Respiratory, Affiliated Hospital of Nanjing University of Chinese Medicine, Nanjing, Jiangsu 210029, China
4Department of Pharmacy, First Affiliated Hospital of Guilin Medical University, Guilin, Guangxi Zhuang Autonomous Region 541001, China
5Department of Infectious Diseases, First Affiliated Hospital of Guilin Medical University, Guilin, Guangxi Zhuang Autonomous Region 541001, China

Correspondence should be addressed to Guoqiang Zhong; gj.zhong@126.com

1. Introduction

Acute myocardial infarction (AMI) has become a global health problem [1]. In 2013, more than 930,000 rural people and 720,000 urban people in China died of AMI, and the number is expected to rise in the next decade [2]. Percutaneous coronary intervention (PCI) and thrombolytic therapy can recover myocardial blood supply in timely manner. These are the most effective treatments for saving the endangered myocardium, reducing the infarct size, maintaining cardiac function, and alleviating ventricular remodeling after infarction [3]. Myocardial ischemia/reperfusion injury (MIRI) causes damage to the function, metabolism, and structure of the heart. It also induces myocardial apoptosis, inflammatory response, and oxidative stress resulting in severe arrhythmia, cardiac failure, and even sudden cardiac death [4]. Although patients with AMI may undergo timely reperfusion therapy, the mortality of MIRI is still 10% [5]. Therefore, there is an urgent need for new drugs that could prevent and treat MIRI.
Apoptosis is an active and orderly cell death process regulated by genes and involves a series of enzymes and is currently the recognized mechanism of MIRI [6]. Studies have demonstrated the occurrence of apoptosis in early stages of myocardial infarction which increases significantly during reperfusion and these are important ways for myocardial cell death in AMI and MIRI [7, 8]. Therefore, inhibition of cardiomyocyte apoptosis may improve cardiac function and alleviate MIRI which is of clinical significance for treating myocardial infarction.

Phosphoinositide 3-kinase-serine/threonine kinase (PI3K/Akt) signaling pathway is an important cell survival mechanism. It has important biological functions in cell survival, apoptosis, and proliferation [9, 10]. Fujio et al. [11] demonstrated that PI3K/Akt signaling pathway serves as an endogenous negative-feedback regulation or compensatory mechanism that could inhibit harmful stimuli-induced apoptotic events. Negoro et al. [12] reported that PI3K/Akt pathway transduces signals that inhibit apoptosis in cardiomyocyte in response to MIRI. Other studies have demonstrated that PI3K/Akt signaling pathway alleviates MIRI by inhibiting cardiomyocyte apoptosis induced by oxidative stress [13–15].

Recent epidemiological studies have shown that extracts from herbs, vegetables, fruits, and spices can reduce the risk of cardiovascular diseases [16, 17]. 6-Gingerol (6-G) is a phenolic substance extracted from ginger. It is a major component of gingerols and has significant antiapoptotic, antioxidative, and anti-inflammatory properties [18, 19]. Sampath et al. [20] showed that 6-G prevents atherosclerosis by inhibiting oxidative stress-induced apoptosis. El-Bakly et al. [21] reported that 6-G has a significant effect in myocardial protection by inhibiting apoptosis through antioxidation and alleviation of doxorubicin-induced myocardial injury.

A previous study found that 6-G had antioxidative effects, inhibiting myocardial cell apoptosis and alleviating MIRI [22]. However the mechanisms of how 6-G prevents apoptosis and MIRI remain unexplored. This study tested the hypothesis that 6-G may activate PI3K/Akt pathway as a possible mechanism of inhibition of apoptosis induced by MIRI.

2. Materials and Methods

2.1. Drugs and Reagents. 6-G (purity, ≥95%) and 2,3,5-triphenyltetrazolium chloride (TTC) were acquired from Sigma Chemical Co. (MO, USA). Cardiac troponin T (cTnT), creatine kinase-MB (CK-MB), caspase-3, PI3K, and Akt enzyme-linked immunosorbent assay (ELISA) kits were obtained from the Casubio Biotech Co. (MD, USA). The terminal deoxynucleotidyl transferase-mediated dUTP-biotin nick end-labeling (TUNEL) apoptosis detection kit was obtained from the Roche Diagnostics (Mannheim, Germany). Caspase-3, PI3K, p-Akt, Akt, and β-tubulin antibodies were purchased from Cell Signaling Technology, Inc. (MA, USA); BCA protein quantitative assay kit and secondary antibodies were procured from Beyotime Biotechnology, Inc. (Changsha, China).

2.2. Animals and Establishment of Rat Myocardial I/R Mode. Sprague-Dawley male rats (weighing 200–280 g) were supplied by the Laboratory Animal Center (SCXX [Gui] 2014-0003) of Guangxi Medical University. All of the procedures and protocols used in our experiments were approved by the Ethics Committee for the Experimental Use of Animals in Guangxi Medical University. Rats were housed in cages under standard experimental conditions, at 20°C–25°C with the humidity of 50%–60% in 12-h light/dark cycle. Animals were allowed free access to standard tap water and rodent chow.

Thirty-two rats were randomized into four groups with sample number of eight for each group. (1) Sham group: rats in this group underwent surgery, but the left anterior descending coronary artery (LAD) was not ligated; (2) 6-G (6 mg/kg) group: the tail vein was injected with 6-G in this group 30 min before surgery; LAD was not ligated; (3) I/R group: the LAD was ligated for 30 min followed by reperfusion for 2 h; (4) 6-G (6 mg/kg) + I/R group: the tail vein was injected 30 min before surgery and LAD was ligated for 30 min. Finally, reperfusion was performed for 2 h.

Rats were intraperitoneally anesthetized using 4% chloral hydrate (10 mL/kg), with dosage maintained at 0.5 mL/kg for the study. After tracheal intubation, ventilation was introduced using a small-animal ventilator at the respiratory rate of 80–90 cycles/min, the expiratory-to-inspiratory ratio of 2:1, and the tidal volume of 8–10 mL/kg. Then, a left thoracotomy was done in the 4th intercostal space. Subsequently, to expose the heart, the LAD was ligated with 6-0 thread. The ligation thread was loosened after a 30 min ischemia, and then a 2 h reperfusion was performed. Limb-lead electrocardiographic electrodes were inserted into the limbs of the rats and electrocardiographic changes were monitored. Elevation of electrocardiogram (ECG) ST-segment and gray-white or swollen myocardium in the blood supply area of ligated blood vessels indicated that the model was successfully established.

2.3. Heart Function Measurement. The invasive hemodynamics evaluation method was used to evaluate the cardiac dysfunction caused by ischemia reperfusion. One end of a microtubing was intubated into the rat left ventricle through its right common carotid artery, while the other end was connected to MS400 biological signal analysis system (Longfeida Technology Co., Ltd., Shandong, China). After reperfusion, left ventricular ejection fraction (EF), left ventricular fractional shortening (FS), left ventricular end systolic diameter (LVESD), left ventricular end diastolic diameter (LVEDd), and maximum rise/down velocity of left intraventricular pressure (±d.dp/dt max) were recorded. Data used for statistical analysis was the mean value of three cardiac cycles.

2.4. 2,3,5-Triphenyltetrazolium Chloride, Hematoxylin, and Eosin Staining Method for Infarct Size and Histopathological Examination of Myocardial Tissues. The infarct size of heart was determined by 1% TTC staining method following the manufacturer’s instructions. Briefly, at completion of reperfusion, the hearts samples were collected and placed at −20°C for 20 min and then sliced into approximately 2 mm thick specimens which were then incubated for 20 min.
in 1% TTC at 37°C. White represents infarct area and red indicates noninfarct area, while the infarct size was measured by Image-Pro Plus 6.0 software. The myocardial tissue was fixed in 4% paraformaldehyde, embedded in paraffin, and subsequently stained with hematoxylin and eosin (H&E). Myocardial injury was observed using an optical microscope (CKX41, Olympus, Tokyo, Japan). MIRI was scored according to the following morphological criteria, as defined as described [23]. Score 0: zero damage; Score 1: mild with interstitial edema and local necrosis; Score 2: moderate with extensive myocardial cell swelling and local necrosis; Score 3: severe with contraction band, capillary compression necrosis, and inflammatory cell infiltration; Score 4: highly severe with diffuse necrosis with contraction bands, compressed capillaries, and hemorrhage.

2.5. ELISA for Serum Cardiac Troponin T and Creatine Kinase-MB Levels. At completion of reperfusion, the arterial blood samples were collected in a vacuum tube containing heparin and centrifuged at 3000g and 4°C for 15 min. The cTnT and CK-MB levels were determined using ELISA kits following the manufacturer's instructions.

2.6. TUNEL Assay for Apoptosis in Cardiomyocyte. TUNEL assays were performed to detect myocardial apoptosis using a commercial kit based on the manufacturer's instructions. The apoptotic cell nuclei was stained green and normal nuclei stained blue. Six fields at a magnification of ×200 were randomly selected from each sample using an optical microscope. The calculation of apoptosis index (AI) was performed as the ratio of TUNEL-positive nuclei to the total number of nuclei stained in each field. Image-Pro Plus 6.0 software was employed in our data analysis.

2.7. ELISA for Caspase-3, PI3K, and Akt Expression in Myocardial Tissues. Caspase-3, PI3K, and Akt expression in myocardial homogenates were measured using caspase-3, PI3K, and Akt ELISA kits following the manufacturer's instructions.

2.8. Western Blot for Caspase-3, PI3K, p-Akt, and Akt Expression in Myocardial Tissues. Myocardial tissue (100 mg) was placed at the globular site of a homogenizer and cut into small pieces with clean scissors. The tissue was homogenized in RIPA buffer containing phenylmethylsulfonyl fluoride (PMSF) on ice for 30 min. The lysate was then transferred to 1.5 ml tubes and centrifuged at 10000–14000g for 5–10 min at 4°C. The supernatant was boiled for 5 min and protein concentration was determined with BCA test kit. Proteins were run on sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE) and subsequently transferred onto the polyvinylidene difluoride-plus (PVDF) membrane. Then the PVDF membrane was incubated overnight with caspase-3 (1:1000), PI3K (1:1000), p-Akt (1:1000), Akt (1:1000), or β-tubulin (1:1000). Blots were washed and incubated with secondary antibody (1:16000) for 2 h at room temperature. The blots were developed using chemiluminescence system (Amersham Pharmacia). The relative density data was collected and analyzed by Image-Pro Plus 6.0 software.

2.9. Statistical Data Analysis. Statistical analysis was carried out using the SPSS statistical package (version 21.0; IBM, NY, USA). All results are shown as mean ± standard deviation. Differences between separate groups were evaluated using one-way analysis of variance. P values of < 0.05 are considered as statistically significant.

3. Results

3.1. The Representative Changes in ECG Were Used to Verify the Success of the I/R Model and the Effects of Pretreatment with 6-G on the ECG Pattern. To confirm the success of the I/R model, we examined the ECG changes. As shown in Figure 1, the ECG pattern was not found to vary in the Sham group and 6-G group. In contrast, remarkable elevation in ST-segment and reperfusion arrhythmia were found in the I/R group, while both were diminished markedly in 6-G pretreatment group.

3.2. Pretreatment with 6-G Promotes Recovery of Cardiac Dysfunction in Response to I/R. To explore the function of 6-G on heart dysfunction recovery after ischemia reperfusion, we followed the changes of EF, FS, LVESD, LVEDd, +dp/dt max, and −dp/dt max in our experiment. As shown in Figures 2(a) and 2(b), EF and FS in I/R group decreased significantly, while both increased markedly in 6-G pretreatment group (P < 0.05). Meanwhile, LVESD and LVEDd in the 6-G pretreatment group decreased significantly (P < 0.05, Figures 2(c) and 2(d)), while +dp/dt max and −dp/dt max increased markedly (P < 0.05, Figures 2(e) and 2(f)), compared to the I/R group.

3.3. Pretreatment with 6-G Reverses Infract Size, Histopathological Changes, and Myocardial Injury Induced by I/R. To study the protective effect of 6-G on I/R-induced myocardial injury, we monitored myocardial infract size and histopathological changes using TTC and H&E staining. Markers of myocardial damage (cTnT and CK-MB) were also determined in the serum. As shown in Figures 3(a) and 3(c), myocardial infarct size was not found in the Sham group and 6-G group; myocardial structure in the Sham group and 6-G group indicated a regular arrangement, normal myocardial fibers, and no necrosis. In contrast, severe myocardial infract size and damage were found in the I/R group, including ruptured cardiac muscle fibers, inflammatory cell infiltration, and edema. Importantly, myocardial tissues from animals pretreated with 6-G prior to I/R exhibited fewer infract size and histopathological changes compared to the I/R group. Also, 6-G treated group had significantly lower cTnT and CK-MB levels relative to the I/R group (P < 0.05, Figures 3(e) and 3(f)).

3.4. Pretreatment with 6-G Inhibits I/R-Induced Apoptosis in Myocardial Tissues. We confirmed the antiapoptotic effects of 6-G by TUNEL and by the protein expression of caspase-3 and cleaved caspase-3. As shown in Figure 4(a), the number of positive cells of TUNEL in the I/R group increased significantly (P < 0.05) compared to the Sham group. In contrast, number of negative cells of TUNEL in 6-G pretreatment
Figure 1: Representative changes in ECG of the I/R model and the effects of pretreatment with 6-G (6 mg/kg) on the ECG pattern.

Figure 2: Pretreatment with 6-G (6 mg/kg) improved cardiac dysfunction induced by I/R. (a) EF, left ventricular ejection fraction. (b) FS, left ventricular fractional shortening. (c) LVESD, left ventricular end systolic diameter. (d) LVEDd, left ventricular end diastolic diameter. (e) \(+\frac{dp}{dt_{\text{max}}}, \) maximum rise velocity of left intraventricular pressure. (f) \(-\frac{dp}{dt_{\text{max}}}, \) maximum down velocity of left intraventricular pressure. Note that \(^aP < 0.05\) against the Sham group; \(^bP < 0.05\) against the I/R group.

Group decreased markedly compared to the I/R group \((P < 0.05)\). To further confirm the antiapoptotic effects of 6-G, we used ELISA to investigate the expression of caspase-3 in myocardial homogenates and to investigate the expression of cleaved caspase-3 in the cardiac tissues by western blot. As shown in Figure 4(c), the expression of caspase-3 in the I/R group increased significantly \((P < 0.05)\) compared to the Sham group, whereas the expression of caspase-3 in the 6-G pretreatment group decreased significantly compared to the I/R group \((P < 0.05)\). As shown in Figure 4(e), the expression of cleaved caspase-3 in the I/R group increased significantly \((P < 0.05)\) compared to the Sham group, and this effect was overcome also by 6-G pretreatment \((P < 0.05)\). All of these results suggest that 6-G reduces cardiac damage induced by ischemia reperfusion via its antiapoptotic effects.

3.5. Pretreatment with 6-G Activates PI3K/Akt Signaling Pathway. We next investigated the expression of PI3K and Akt
in myocardial homogenates by ELISA and the expression of PI3K, p-Akt, and Akt in the cardiac tissues by western blot in response to I/R in the presence or absence of 6-G. PI3/Akt pathway has been previously reported to overcome MIRI-induced apoptosis in cardiomyocyte [12]. In myocardial homogenates, as demonstrated in Figures 5(a) and 5(b), PI3K and Akt expression was reduced in I/R group and this effect was reversed in 6-G pretreatment group ($P < 0.05$). A corresponding decrease in protein levels of PI3K, p-Akt, and Akt was also observed in the I/R group compared to the Sham group. Pretreatment with 6-G protected against the inhibitory effect of I/R on these proteins ($P < 0.05$, Figures 5(e), 5(f), and 5(g)).

4. Discussion

In the present investigation, we report a previously unknown mechanism of protective effects of 6-G against MIRI. Our findings reveal that 6-G promotes recovery of cardiac dysfunction, alleviates infarct size and pathological changes in myocardial tissues; reduces CK-MB and cTnT levels; and inhibit cardiomyocyte apoptosis induced by I/R. It also upregulates the expression of PI3K/Akt signaling pathway.

MIRI is a complex pathophysiological process implicated in apoptosis, inflammatory response, and oxidative stress [24]. Apoptosis is an important form of cardiomyocyte death in the early stage of MIRI and is crucial in the pathophysiology of MIRI, which further leads to severe complications such as arrhythmia and heart failure [25, 26]. An experimental study found that cardiomyocyte injury of rats was aggravated after I/R, showing typical changes in morphological phenotype of cell apoptosis [27]. Cardiomyocyte apoptosis increased significantly in the reperfusion group than in the permanent ischemia group [28]. A clinical study found that cardiomyocyte apoptosis occurred in patients with acute coronary syndrome before and after PCI [29]. In patients with

![Figure 3: Pretreatment with 6-G (6 mg/kg) reversed infarct size, histopathological changes, and myocardial injury induced by I/R. (a) Representative images of TTC stained samples. White represents infarct area and red indicates noninfarct area. The infarct size can then be measured using Image-Pro Plus 6.0 software. (b) Infarct size score. (c) Representative images of H&E stained samples ($\times$200). (d) Damage score. (e) Serum level of cTnT. (f) Serum level of CK-MB. Note that $^A P < 0.05$ against the Sham group; $^B P < 0.05$ against the I/R group.](image)
AMI, DNA strand breaks in cardiomyocyte were observed in the regions adjacent to and further away from the necrotic myocardium. This was further confirmed by DNA gradient gel electrophoresis and apoptotic morphologies showed typical changes [30].

I/R may lead to activation of cascade of apoptotic proteins called caspases. A recent study found that more than 14 kinds of caspases were involved in regulating cell apoptosis. Among these, caspase-3 is the main executor of cell apoptosis which directly causes cell death, intracellular protein dissolution, and degradation of enzymes and DNA [31]. An experimental study showed that melatonin downregulates expression of caspase-3 to alleviate MIRI by activating sirtuin-3 signaling pathway and by increasing the expression of Tom70 [32, 33]. Vanillyl alcohol reduces the activation of caspase-3 to alleviate MIRI by antioxidation [34]. Schisandrin B downregulates expression of caspase-3 to attenuate endoplasmic reticulum stress-induced cardiomyocyte apoptosis via transcription factor 6 and (PKR-) like ER kinase signaling pathways, further alleviating MIRI [35]. These findings suggest that downregulation of expression of caspase-3 may alleviate MIRI. In the present study, we found that 6-G downregulated
Figure 5: Pretreatment with 6-G (6 mg/kg) activated the PI3K/Akt signaling pathway. ((a) and (b)) PI3K and Akt activities in myocardial homogenates detected by ELISA. ((c) and (d)) The expression level of PI3K, p-Akt, and Akt in the myocardial tissues detected using western blot and quantitative analyses ((e), (f), and (g)). Note that A $p < 0.05$ against the Sham group; B $p < 0.05$ against the I/R group.

The caspase-3 expression to inhibit cardiomyocyte apoptosis and alleviated myocardial injury during reperfusion.

Recent studies have demonstrated PI3K/Akt signaling pathway to be important for myocardial protection. It regulates survival and apoptosis of cardiomyocyte by regulating the integrity of cardiomyocyte morphology, protein synthesis, and metabolic function [36, 37]. Various studies have underscored the involvement of PI3/Akt pathway in protecting against MIRI-induced apoptosis. Neural precursor cell expressed developmentally downregulated 4-1 (NEDD4-1) was found to downregulate expression of caspase-3 to protect against cardiomyocyte apoptosis generated through I/R by activating PI3K/Akt signaling pathway [38]. Also, microRNA-214 regulates expression of phosphatase and tensin homolog by activating PI3K/Akt pathway and down-regulating caspase-3 expression to alleviate I/R-induced cardiomyocyte apoptosis [39]. Another study reported that Gypenoside inhibits cardiomyocyte apoptosis by activating PI3K/Akt in vivo and in vitro to protect against MIRI [40]. These results confirm that activating the signaling pathway of PI3K/Akt in the heart may alleviate MIRI.

In the present study, we found that 6-G activated PI3K/Akt signaling pathway as a possible mechanism of apoptosis inhibition in response to MIRI. However, the present study has some limitations. Firstly, the main purpose of our study is the preventive effect of 6-G. We thus focused on evaluating the use of 6-G before PCI or thrombolysis to reduce the subsequent appearance of MIRI. The study of 6-G treatment effect after ligation of LAD will be conducted in a subsequent and separate study. Secondly, the findings in our experiments were based on a vivo animal model, but not from direct clinical situations of ST-segment elevation myocardial infarction (STEMI). Further investigation will be needed to verify our findings in clinical scenario. Thirdly, this study did not use inhibitors of PI3K/Akt signaling pathway such as LY294002 or wortmannin or siRNA approach and these research results are part of a separate investigation of ours. We are currently conducting the PI3K/Akt signaling pathway blockade study. In conclusion, the current study shows that 6-G alleviates MIRI by inhibiting I/R-induced cardiomyocyte apoptosis and that 6-G directly or indirectly activates PI3K/Akt signaling pathway. These experimental
results suggest that the application of 6-G may offer a new strategy for preventing MIRI.

Conflicts of Interest

The authors declare that there are no conflicts of interest regarding the publication of this paper.

Authors’ Contributions

Xiangwei Lv and Tongtong Xu contributed equally to this work and should be considered co-first authors.

Acknowledgments

This study was supported by grants from the National Natural Science Foundation of China (no. 81760861); Guangxi Province Science and Technology Research and Development Program (no. 1598025-29); Guili Science and Technology Research and Development Program (no. 20160226-1-1); Innovation Project of Guangxi Graduate Education (no. YCBZ2017034); and Guangxi University Science and Technology Research Project (no. KY2015LX250).

References

[1] GBD 2013 Mortality and Causes of Death Collaborators, "Global, regional, and national age-sex specific all-cause and cause-specific mortality for 240 causes of death, 1990-2013: a systematic analysis for the Global Burden of Disease Study 2013," The Lancet, vol. 385, no. 9963, pp. 167–175, 2013.

[2] W. Chen, R. Gao, L. Liu et al., "Outline of the report on cardiovascular diseases in China, 2014," European Heart Journal Supplements, vol. 18, pp. F2–F11, 2016.

[3] P. W. Armstrong, A. H. Gershlick, P. Goldstein et al., "Fibrinolysis or primary PCI in ST-segment elevation myocardial infarction," The New England Journal of Medicine, vol. 368, no. 15, pp. 1379–1387, 2013.

[4] P. Libby, "Mechanisms of acute coronary syndromes and their implications for therapy," The New England Journal of Medicine, vol. 368, no. 21, pp. 2004–2013, 2013.

[5] E. C. Keeley, J. A. Boura, and C. L. Grines, "Primary angioplasty versus intravenous thrombolytic therapy for acute myocardial infarction: A quantitative review of 23 randomised trials," The Lancet, vol. 361, no. 9351, pp. 13–20, 2003.

[6] S. Ghaderi, N. Alkadadi, N. Dilaver et al., "Role of glyco- gen synthase kinase following myocardial infarction and ischemia–reperfusion," Apoptosis, vol. 22, no. 7, pp. 887–897, 2017.

[7] E. A. W. J. Dumont, L. Hofstra, W. L. Van Heerde et al., "Cardiomyocyte death induced by myocardial ischemia and reperfusion: Measurement with recombinant human annexin-V in a mouse model," Circulation, vol. 102, no. 13, pp. 1564–1568, 2000.

[8] L. Hofstra, I. H. Liem, E. A. Dumont et al., "Visualisation of cell death in vivo in patients with acute myocardial infarction," The Lancet, vol. 356, no. 9225, pp. 209–212, 2000.

[9] X. Hu, C. Xu, X. Zhou, B. Cui, Z. Lu, and H. Jiang, "PI3K/Akt signaling pathway involved in cardioprotection of preconditioning with high mobility group box 1 protein during myocardial ischemia and reperfusion," International Journal of Cardiology, vol. 150, no. 2, pp. 222–223, 2011.

[10] T. Ha, F. Hua, X. Liu et al., "Lipopolysaccharide-induced myocardial protection against ischaemia/reperfusion injury is mediated through a PI3K/Akt-dependent mechanism," Cardiovascular Research, vol. 78, no. 3, pp. 546–553, 2008.

[11] Y. Fujio, T. Nguyen, D. Wenck, R. N. Kitsis, and K. Walsh, "Akt promotes survival of cardiomyocytes in vitro and protects against ischemia-reperfusion injury in mouse heart," Circulation, vol. 101, no. 6, pp. 660–667, 2000.

[12] S. Negoro, H. Oh, E. Tone et al., "Glycoprotein 130 regulates cardiac myocyte survival in doxorubicin-induced apoptosis through phosphatidylinositol 3-kinase/Akt phosphorylation and Bcl-xL/caspase-3 interaction," Circulation, vol. 103, no. 4, pp. 555–561, 2001.

[13] Y.-Q. Jiang, G.-L. Chang, Y. Wang, D.-Y. Zhang, L. Cao, and J. Liu, "Geniposide Prevents Hypoxia/Reoxygenation-Induced Apoptosis in H9c2 Cells: Improvement of Mitochondrial Dysfunction and Activation of GLP-1R and the PI3K/AKT Signaling Pathway," Cellular Physiology and Biochemistry, vol. 39, no. 1, pp. 407–421, 2016.

[14] Y. Sun, C. Jiang, J. Jiang, and L. Qiu, "Dexametomidine protects mice against myocardium ischaemic/reperfusion injury by activating an AMPK/PI3K/Akt/eNOS pathway," Clinical and Experimental Pharmacology and Physiology, vol. 44, no. 9, pp. 946–953, 2017.

[15] C.-W. Liu, F. Yang, S.-Z. Cheng, Y. Liu, L.-H. Wan, and H.-L. Cong, "Rosuvastatin postconditioning protects isolated hearts against ischemia–reperfusion injury: The role of radical oxygen species, PI3K–Akt–GSK-3β pathway, and mitochondrial permeability transition pore," Cardiovascular Therapeutics, vol. 35, no. 1, pp. 3–9, 2017.

[16] P. J. Mink, C. G. Scafford, L. M. Barraj et al., "Flavonoid intake and cardiovascular disease mortality: A prospective study in postmenopausal women," American Journal of Clinical Nutrition, vol. 85, no. 3, pp. 895–909, 2007.

[17] H.-J. Wu, J.-Y. Yang, M. Jin et al., "Glycyrrhetinic acid protects the heart from ischemia/reperfusion injury by attenuating the susceptibility and incidence of fatal ventricular arrhythmia during the reperfusion period in the rat hearts," Cellular Physiology and Biochemistry, vol. 36, no. 2, pp. 741–752, 2015.

[18] J. Krell and J. Stebbing, "Ginger: The root of cancer therapy?" The Lancet Oncology, vol. 13, no. 3, pp. 235–236, 2012.

[19] Y. Li, B. Xu, and M. Xu, "6-Gingerol protects intestinal barrier from ischemia/reperfusion-induced damage via inhibition of p38 MAPK to NF-κB signalling," Pharmacological Research, vol. 119, pp. 137–148, 2017.

[20] C. Sampath, S. Sang, and M. Ahmedna, "In vitro and in vivo inhibition of aldose reductase and advanced glycation end products by phloretin, epigallocatechin 3-gallate and [6]-gingerol," Biomedicine & Pharmacotherapy, vol. 84, pp. 502–513, 2016.

[21] W. M. El-Bakly, M. L. Louka, A. M. El-Halawany, and M. F. Schaalan, "6-Gingerol ameliorated doxorubicin-induced cardio toxicity: role of nuclear factor kappa B and protein glyca tion," Cancer Chemotherapy and Pharmacology, vol. 70, no. 6, pp. 833–841, 2012.

[22] X. Lv and T. Xu, "6-Gingerol inhibits oxidative stress amelio rated myocardial ischemia/reperfusion injury in rats," Journal of Clinical Cardiology (China), vol. 33, pp. 575–579, 2017, (In Chinese with English abstract).
[23] R. Aneja, P. W. Hake, T. J. Burroughs, A. G. Denenberg, H. R. Wong, and B. Zingarelli, “Epigallocatechin, a green tea polyphenol, attenuates myocardial ischemia reperfusion injury in rats,” *Molecular Medicine*, vol. 10, no. 1-6, pp. 55–62, 2004.

[24] X. Li, X. Hu, J. Wang et al., “Short-Term Hesperidin Pretreatment Attenuates Rat Myocardial Ischemia/Reperfusion Injury by Inhibiting High Mobility Group Box 1 Protein Expression via the PI3K/Akt Pathway,” *Cellular Physiology and Biochemistry*, vol. 39, no. 5, pp. 1850–1862, 2016.

[25] D. M. Yellon and D. J. Hausenloy, “Myocardial reperfusion injury,” *The New England Journal of Medicine*, vol. 357, no. 11, pp. 1074–1135, 2007.

[26] D. S. Burley, P. Ferdinandy, and G. F. Baxter, “Cyclic GMP and protein kinase-G in myocardial ischaemia-reperfusion: opportunities and obstacles for survival signaling,” *British Journal of Pharmacology*, vol. 152, no. 6, pp. 855–869, 2007.

[27] H. Fliss and D. Gattinger, “Apoptosis is ischemic and reperfused rat myocardium,” *Circulation Research*, vol. 79, no. 5, pp. 949–956, 1996.

[28] Z.-Q. Zhao, M. Nakamura, N.-P. Wang et al., “Reperfusion induces myocardial apoptotic cell death,” *Cardiovascular Research*, vol. 45, no. 3, pp. 651–660, 2000.

[29] T. Xu, D. Li, and D. Jiang, “Targeting cell signaling and apoptotic pathways by luteolin: cardioprotective role in rat cardiomyocytes following ischemia/reperfusion,” *Nutrients*, vol. 4, no. 12, pp. 2008–2019, 2012.

[30] G. Olivetti, F. Quaini, R. Sala et al., “Acute myocardial infarction in humans is associated with activation of programmed myocyte cell death in the surviving portion of the heart,” *Journal of Molecular and Cellular Cardiology*, vol. 28, no. 9, pp. 2005–2016, 1996.

[31] A. Kim, N.-H. Yim, and J. Y. Ma, “Samsoeum, a traditional herbal medicine, elicits apoptotic and autophagic cell death by inhibiting Akt/mTOR and activating the JNK pathway in cancer cells,” *BMC Complementary and Alternative Medicine*, vol. 13, article 233, 2013.

[32] M. Zhai, B. Li, W. Duan et al., “Melatonin ameliorates myocardial ischemia reperfusion injury through SIRT3-dependent regulation of oxidative stress and apoptosis,” *Journal of Pineal Research*, vol. 63, no. 2, Article ID e12419, 2017.

[33] H.-F. Pei, J.-N. Hou, F.-P. Wei et al., “Melatonin attenuates post-myocardial infarction injury via increasing Tom70 expression,” *Journal of Pineal Research*, vol. 62, no. 1, Article ID e12371, 2017.

[34] S. Bae, M. Park, C. Kang et al., “Hydrogen Peroxide-Responsive Nanoparticle Reduces Myocardial Ischemia/Reperfusion Injury,” *Journal of the American Heart Association*, vol. 5, no. 11, 2016.

[35] W. Zhang, Z. Sun, and F. Meng, “Schisandrin B Ameliorates Myocardial Ischemia/Reperfusion Injury Through Attenuation of Endoplasmic Reticulum Stress-Induced Apoptosis,” *Inflammation*, pp. 1–9, 2017.

[36] H. K. Siddall, C. E. Warrell, D. M. Yellon, and M. M. Mocanu, “Ischemia-reperfusion injury and cardioprotection: Investigating PTEN, the phosphatase that negatively regulates PI3K, using a congenital model of PTEN haploinsufficiency,” *Basic Research in Cardiology*, vol. 103, no. 6, pp. 560–568, 2008.

[37] F. Damilano, A. Perino, and E. Hirsch, “PI3k kinase and scaffold functions in heart,” *Annals of the New York Academy of Sciences*, vol. 1188, pp. 39–45, 2010.

[38] W. Hu, P. Zhang, J. Gu, Q. Yu, and D. Zhang, “NEDD4-1 protects against ischaemia/reperfusion-induced cardiomyocyte apoptosis via the PI3K/Akt pathway,” *Apoptosis*, vol. 22, no. 3, pp. 437–448, 2017.

[39] X. Wang, T. Ha, Y. Hu et al., “MicroRNA-214 protects against hypoxia/reoxygenation induced cell damage and myocardial ischemia/reperfusion injury via suppression of PTEN and Biml expression,” *Oncotarget*, vol. 7, no. 52, pp. 86926–86936, 2016.

[40] H. Yu, H. Zhang, W. Zhao et al., “Gypenoside Protects against Myocardial Ischemia-Reperfusion Injury by Inhibiting Cardiomyocytes Apoptosis via Inhibition of CHOP Pathway and Activation of PI3K/Akt Pathway in Vivo and in Vitro,” *Cellular Physiology and Biochemistry*, vol. 39, no. 1, pp. 123–136, 2016.